Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

J. Ring; M. Worm; A. Wollenberg; J. P. Thyssen; T. Jakob; L. Klimek; C. Bangert; S. Barbarot; T. Bieber; M. S. de Bruin-Weller; P. V. Chernyshov; S. Christen-Zaech; M. Cork; U. Darsow; C. Flohr; R. Fölster-Holst; C. Gelmetti; U. Gieler; J. Gutermuth; A. Heratizadeh; D. J. Hijnen; L. B. von Kobyletzki; B. Kunz; C. Paul; L. de Raeve; J. Seneschal; D. Simon; P. I. Spuls; J. F. Stalder; A. Svensson; Z. Szalai; A. Taieb; A. Torrelo; M. Trzeciak; C. Vestergaard; T. Werfel; S. Weidinger; M. Deleuran

doi:https://doi.org/10.1111/jdv.17237

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

J. Ring, M. Worm, A. Wollenberg, J. P. Thyssen, T. Jakob, L. Klimek, C. Bangert, S. Barbarot, T. Bieber, M. S. de Bruin-Weller, P. V. Chernyshov, S. Christen-Zaech, M. Cork, U. Darsow, C. Flohr, R. Fölster-Holst, C. Gelmetti, U. Gieler, J. Gutermuth, A. HeratizadehD. J. Hijnen, L. B. von Kobyletzki, B. Kunz, C. Paul, L. de Raeve, J. Seneschal, D. Simon, P. I. Spuls, J. F. Stalder, A. Svensson, Z. Szalai, A. Taieb, A. Torrelo, M. Trzeciak, C. Vestergaard, T. Werfel, S. Weidinger, M. Deleuran

Research output: Contribution to journal › Comment/Letter to the editor › Academic

27 Citations (Scopus)

Original language	English
Pages (from-to)	e362-e365
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	35
Issue number	6
Early online date	2021
DOIs	https://doi.org/10.1111/jdv.17237
Publication status	Published - Jun 2021

Access to Document

https://doi.org/10.1111/jdv.17237

Cite this

Ring, J., Worm, M., Wollenberg, A., Thyssen, J. P., Jakob, T., Klimek, L., Bangert, C., Barbarot, S., Bieber, T., de Bruin-Weller, M. S., Chernyshov, P. V., Christen-Zaech, S., Cork, M., Darsow, U., Flohr, C., Fölster-Holst, R., Gelmetti, C., Gieler, U., Gutermuth, J., ... Deleuran, M. (2021). Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 35(6), e362-e365. https://doi.org/10.1111/jdv.17237

@article{1ad3a46f4cea48819d90c46c4336ba31,

title = "Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts",

author = "J. Ring and M. Worm and A. Wollenberg and Thyssen, {J. P.} and T. Jakob and L. Klimek and C. Bangert and S. Barbarot and T. Bieber and {de Bruin-Weller}, {M. S.} and Chernyshov, {P. V.} and S. Christen-Zaech and M. Cork and U. Darsow and C. Flohr and R. F{\"o}lster-Holst and C. Gelmetti and U. Gieler and J. Gutermuth and A. Heratizadeh and Hijnen, {D. J.} and {von Kobyletzki}, {L. B.} and B. Kunz and C. Paul and {de Raeve}, L. and J. Seneschal and D. Simon and Spuls, {P. I.} and Stalder, {J. F.} and A. Svensson and Z. Szalai and A. Taieb and A. Torrelo and M. Trzeciak and C. Vestergaard and T. Werfel and S. Weidinger and M. Deleuran",

note = "Funding Information: Dr. Ring has been an advisor or speaker for AbbVie, Allergika, Sanofi‐Genzyme, Pfizer, Bencard, LEO Pharma, and Mylan. Dr. Thyssen has attended advisory boards for Eli‐Lilly, Regeneron, Pfizer, LEO Pharma, Abbvie and Sanofi‐Genzyme, received speaker honorarium from LEO Pharma, Abbvie, Regeneron, and Sanofi‐Genzyme, and received research grants from Regeneron and Sanofi‐Genzyme. Dr. Vestergaard has been investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr Barbarot has been a principal investigator, advisory board member, or consultant for Pierre Fabre Laboratory, Bioderma, Laboratoire La Roche Posay, Sanofi‐Genzyme, Abbvie, Novartis, Janssen, Leo‐Pharma, Pfizer, Amgen, Lilly. Dr. de Bruin‐Weller has been a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi‐Genzym. Dr. Bieber has been a principal investigator, advisory board member, or consultant for Regeneron, Sanofi, GSK, Celgene, Abbvie, AnaptysBio, MedImmune, Chugai, Pierre Fabre, Novartis, Asana Biosciences, LEO, Galapagos/MorphoSys, BioVerSys, Galderma, Kymab, Glenmark, Astellas, Daiichi‐Sankyo, Lilly, Pfizer, MenloTx, Dermavant, Allmiral. Dr. T. Bieber was speaker, and/or consultant and/or Investigator for AbbVie, Allmiral, AnaptysBio, Arena, Asana Biosciences, Astellas, BioVerSys, B{\"o}hringer‐Ingelheim, Celgene, Daichi‐Sankyo, Dermavant/Roivant, DermTreat, DS Pharma, RAPT/FLX Bio, Galapagos/MorphoSys, Galderma, Glenmark, GSK, Incyte, Kymab, LEO, Lilly, L´Or{\'e}al, MenloTx, Novartis, Pfizer, Pierre Fabre, Sanofi/Regeneron, UCB. T. Bieber is founder of the non‐profit biotech company “Davos Biosciences”. Dr. Gutermuth has been a consultant, advisory board member and/or speaker for AbbVie, Almirall, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi‐Genzyme. Dr Ta{\"i}eb has been a consultant or investigator for Pierre Fabre, Galderma, Novartis, Johnson and Johnson, Incyte, Abbvie, Modilac, Pfizer, Lilly, Arena, Bioderma, Sanofi. Dr. Seneschal has been an investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr. Weidinger has received institutional research grants from LEO Pharma and L{\textquoteleft}Oreal, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Incyte, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Regeneron, LEO Pharma, Abbvie and Galderma, and is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of atopic dermatitis. Dr. Trzeciak has been a speaker, consultant, investigator or advisory board member for LEO Pharma, Pierre Fabre, Pfizer, La Roche Posay, Sanofi Genzyme, Novartis, Bioderma, Mead Johnson. Dr. Cork is an Investigator and/or consultant Consultant for Regeneron, Sanofi Genzyme, Pfizer, LEO, Galapagos, Novartis, Boots, L{\textquoteright}Oreal, Reckitt Benckiser, Oxagen, Johnson&Johnson, Hyphens, Kymab, Astellas, Galderma, Procter&Gamble, Abbvie, Lilly, Galderma, Menlo, Perrigo. Dr Paul has received grants and been a consultant for Allmiral, Amgen, Abbvie, Boehringer, Celgene, Eli Lilly & Co, Novartis, Janssen, Pfizer, LEO Pharma, Merck, UCB pharma, Pierre Fabre, Regeneron, Sanofi‐Genzyme. Dr Flohr is chief investigator of the UK National Institute for Health Research‐funded TREAT (ISRCTN15837754) and SOFTER (Clinicaltrials.gov: NCT03270566) trials as well as the UK‐Irish Atopic eczema Systemic Therapy Register (A‐STAR; ISRCTN11210918) and a principal investigator in the European Union Horizon 2020‐funded BIOMAP Consortium ( http://www.biomap‐imi.eu/ ). His department has also received investigator‐led funding from Sanofi‐Genzyme. Dr. Heratizadeh reports personal fees from Leo Pharma, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Sanofi‐Genzyme, personal fees from Beiersdorf, personal fees from Hans Karrer, personal fees from Nutricia, personal fees from Meda, personal fees from Lilly, grants from Janssen, outside the submitted work. Dr. Darsow gave advice to or received an honorarium for talks or research grant from the following companies: ALK‐Abello, Bencard, Meda, Novartis, and Sanofi‐Regeneron outside the submitted work. Dr. Simon has been an investigator, advisory board member, or consultant for AbbVie, AstraZeneca, Galderma, Lilly, Pfizer, Roche Pharma, Sanofi Genzyme. Dr. Torrelo has acted as advisor and/or participant in clinical trials for Sanofi, Lilly, Pfizer, Abbvie, and Mylan. Dr. Chernyshov, Dr. Stalder, Dr. Svensson and Dr. Kunz reports no conflict of interest. Dr. Gelmetti has acted as advisor and/or participant in clinical trials for Bayer, Sanofi/Regeneron, Galderma and has lectured at educational events sponsored by Pfizer and Leo Pharma. Dr Szalai has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Novartis, has lectured at educational events sponsored by Nutricia, is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Dr. von Kobyletzki has been an investigator, speaker, or consultant for Pfizer, Sanofi, LeoPharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/ or received personal fees and non‐financial support from LEO Pharma, Pierre Fabre, Sanofi‐Genzyme and Bioderma. Dr. F{\"o}lster‐Holst reports being consultant/Advisor for Beiersdorf AG, Johnson&Johnson, LEO Pharma, Neubourg, Novartis Pharma AG, Nutricia, Pfizer Inc., Regeneron, Sanofi‐Aventis as well as speaker for Beiersdorf AG, LEO Pharma, Neubourg, Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer, Procter&Gamble, Regeneron, Sanofi‐Aventis. Dr Christen‐Zaechs has been an advisor, speaker or investigator for Galderma, L{\textquoteright}Oreal, La Roche Posey, Pierre Fabre, Procter and Gamble and Sanofi‐Genzyme. Dr. Hijnen has been investigator, speaker, or consultant for Abbvie, Eli Lilly, Incyte, LeoPharma, MedImmune/Astrazeneca, Pfizer, Sanofi, ThermoFisher. Dr. Gieler has received institutional research grants from Galderma, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Abbvie, Novartis, Sebamed and Galderma, and is involved in the organization of atopic dermatitis education programs in Germany for the treatment of atopic dermatitis. Dr. Bangert has been a consultant or speaker for Bayer, Mylan, LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Celgene and AbbVie and principal investigator for Merck, Novartis, Sanofi, Abbvie, Elli Lilly, and Galderma. Dr. Spuls has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), received departmental independent research grants from pharmaceutical industries different since December 2019 for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital and, is Chief Investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigator of the SECURE‐AD registry. Dr. Wollenberg has been a principal investigator, advisory board member, or consultant for AbbVie, Almirall, Galderma, Hans Karrer, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme, and received speaker honoraria from Chugai, Galderma, LEO Pharma, Lilly, Loreal, MedImmune, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. Dr. Deleuran has been a principal investigator, speaker, advisory board member, or consultant for LEO Pharma, AbbVie, Almirall, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Pierre Fabre. This research was performed independently through the authors{\textquoteright} academic university and hospital affiliations.",

year = "2021",

month = jun,

doi = "https://doi.org/10.1111/jdv.17237",

language = "English",

volume = "35",

pages = "e362--e365",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell",

number = "6",

}

Ring, J, Worm, M, Wollenberg, A, Thyssen, JP, Jakob, T, Klimek, L, Bangert, C, Barbarot, S, Bieber, T, de Bruin-Weller, MS, Chernyshov, PV, Christen-Zaech, S, Cork, M, Darsow, U, Flohr, C, Fölster-Holst, R, Gelmetti, C, Gieler, U, Gutermuth, J, Heratizadeh, A, Hijnen, DJ, von Kobyletzki, LB, Kunz, B, Paul, C, de Raeve, L, Seneschal, J, Simon, D, Spuls, PI, Stalder, JF, Svensson, A, Szalai, Z, Taieb, A, Torrelo, A, Trzeciak, M, Vestergaard, C, Werfel, T, Weidinger, S & Deleuran, M 2021, 'Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts', Journal of the European Academy of Dermatology and Venereology, vol. 35, no. 6, pp. e362-e365. https://doi.org/10.1111/jdv.17237

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. / Ring, J.; Worm, M.; Wollenberg, A. et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 35, No. 6, 06.2021, p. e362-e365.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

AU - Ring, J.

AU - Worm, M.

AU - Wollenberg, A.

AU - Thyssen, J. P.

AU - Jakob, T.

AU - Klimek, L.

AU - Bangert, C.

AU - Barbarot, S.

AU - Bieber, T.

AU - de Bruin-Weller, M. S.

AU - Chernyshov, P. V.

AU - Christen-Zaech, S.

AU - Cork, M.

AU - Darsow, U.

AU - Flohr, C.

AU - Fölster-Holst, R.

AU - Gelmetti, C.

AU - Gieler, U.

AU - Gutermuth, J.

AU - Heratizadeh, A.

AU - Hijnen, D. J.

AU - von Kobyletzki, L. B.

AU - Kunz, B.

AU - Paul, C.

AU - de Raeve, L.

AU - Seneschal, J.

AU - Simon, D.

AU - Spuls, P. I.

AU - Stalder, J. F.

AU - Svensson, A.

AU - Szalai, Z.

AU - Taieb, A.

AU - Torrelo, A.

AU - Trzeciak, M.

AU - Vestergaard, C.

AU - Werfel, T.

AU - Weidinger, S.

AU - Deleuran, M.

N1 - Funding Information: Dr. Ring has been an advisor or speaker for AbbVie, Allergika, Sanofi‐Genzyme, Pfizer, Bencard, LEO Pharma, and Mylan. Dr. Thyssen has attended advisory boards for Eli‐Lilly, Regeneron, Pfizer, LEO Pharma, Abbvie and Sanofi‐Genzyme, received speaker honorarium from LEO Pharma, Abbvie, Regeneron, and Sanofi‐Genzyme, and received research grants from Regeneron and Sanofi‐Genzyme. Dr. Vestergaard has been investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr Barbarot has been a principal investigator, advisory board member, or consultant for Pierre Fabre Laboratory, Bioderma, Laboratoire La Roche Posay, Sanofi‐Genzyme, Abbvie, Novartis, Janssen, Leo‐Pharma, Pfizer, Amgen, Lilly. Dr. de Bruin‐Weller has been a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi‐Genzym. Dr. Bieber has been a principal investigator, advisory board member, or consultant for Regeneron, Sanofi, GSK, Celgene, Abbvie, AnaptysBio, MedImmune, Chugai, Pierre Fabre, Novartis, Asana Biosciences, LEO, Galapagos/MorphoSys, BioVerSys, Galderma, Kymab, Glenmark, Astellas, Daiichi‐Sankyo, Lilly, Pfizer, MenloTx, Dermavant, Allmiral. Dr. T. Bieber was speaker, and/or consultant and/or Investigator for AbbVie, Allmiral, AnaptysBio, Arena, Asana Biosciences, Astellas, BioVerSys, Böhringer‐Ingelheim, Celgene, Daichi‐Sankyo, Dermavant/Roivant, DermTreat, DS Pharma, RAPT/FLX Bio, Galapagos/MorphoSys, Galderma, Glenmark, GSK, Incyte, Kymab, LEO, Lilly, L´Oréal, MenloTx, Novartis, Pfizer, Pierre Fabre, Sanofi/Regeneron, UCB. T. Bieber is founder of the non‐profit biotech company “Davos Biosciences”. Dr. Gutermuth has been a consultant, advisory board member and/or speaker for AbbVie, Almirall, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi‐Genzyme. Dr Taïeb has been a consultant or investigator for Pierre Fabre, Galderma, Novartis, Johnson and Johnson, Incyte, Abbvie, Modilac, Pfizer, Lilly, Arena, Bioderma, Sanofi. Dr. Seneschal has been an investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr. Weidinger has received institutional research grants from LEO Pharma and L‘Oreal, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Incyte, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Regeneron, LEO Pharma, Abbvie and Galderma, and is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of atopic dermatitis. Dr. Trzeciak has been a speaker, consultant, investigator or advisory board member for LEO Pharma, Pierre Fabre, Pfizer, La Roche Posay, Sanofi Genzyme, Novartis, Bioderma, Mead Johnson. Dr. Cork is an Investigator and/or consultant Consultant for Regeneron, Sanofi Genzyme, Pfizer, LEO, Galapagos, Novartis, Boots, L’Oreal, Reckitt Benckiser, Oxagen, Johnson&Johnson, Hyphens, Kymab, Astellas, Galderma, Procter&Gamble, Abbvie, Lilly, Galderma, Menlo, Perrigo. Dr Paul has received grants and been a consultant for Allmiral, Amgen, Abbvie, Boehringer, Celgene, Eli Lilly & Co, Novartis, Janssen, Pfizer, LEO Pharma, Merck, UCB pharma, Pierre Fabre, Regeneron, Sanofi‐Genzyme. Dr Flohr is chief investigator of the UK National Institute for Health Research‐funded TREAT (ISRCTN15837754) and SOFTER (Clinicaltrials.gov: NCT03270566) trials as well as the UK‐Irish Atopic eczema Systemic Therapy Register (A‐STAR; ISRCTN11210918) and a principal investigator in the European Union Horizon 2020‐funded BIOMAP Consortium ( http://www.biomap‐imi.eu/ ). His department has also received investigator‐led funding from Sanofi‐Genzyme. Dr. Heratizadeh reports personal fees from Leo Pharma, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Sanofi‐Genzyme, personal fees from Beiersdorf, personal fees from Hans Karrer, personal fees from Nutricia, personal fees from Meda, personal fees from Lilly, grants from Janssen, outside the submitted work. Dr. Darsow gave advice to or received an honorarium for talks or research grant from the following companies: ALK‐Abello, Bencard, Meda, Novartis, and Sanofi‐Regeneron outside the submitted work. Dr. Simon has been an investigator, advisory board member, or consultant for AbbVie, AstraZeneca, Galderma, Lilly, Pfizer, Roche Pharma, Sanofi Genzyme. Dr. Torrelo has acted as advisor and/or participant in clinical trials for Sanofi, Lilly, Pfizer, Abbvie, and Mylan. Dr. Chernyshov, Dr. Stalder, Dr. Svensson and Dr. Kunz reports no conflict of interest. Dr. Gelmetti has acted as advisor and/or participant in clinical trials for Bayer, Sanofi/Regeneron, Galderma and has lectured at educational events sponsored by Pfizer and Leo Pharma. Dr Szalai has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Novartis, has lectured at educational events sponsored by Nutricia, is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Dr. von Kobyletzki has been an investigator, speaker, or consultant for Pfizer, Sanofi, LeoPharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/ or received personal fees and non‐financial support from LEO Pharma, Pierre Fabre, Sanofi‐Genzyme and Bioderma. Dr. Fölster‐Holst reports being consultant/Advisor for Beiersdorf AG, Johnson&Johnson, LEO Pharma, Neubourg, Novartis Pharma AG, Nutricia, Pfizer Inc., Regeneron, Sanofi‐Aventis as well as speaker for Beiersdorf AG, LEO Pharma, Neubourg, Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer, Procter&Gamble, Regeneron, Sanofi‐Aventis. Dr Christen‐Zaechs has been an advisor, speaker or investigator for Galderma, L’Oreal, La Roche Posey, Pierre Fabre, Procter and Gamble and Sanofi‐Genzyme. Dr. Hijnen has been investigator, speaker, or consultant for Abbvie, Eli Lilly, Incyte, LeoPharma, MedImmune/Astrazeneca, Pfizer, Sanofi, ThermoFisher. Dr. Gieler has received institutional research grants from Galderma, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Abbvie, Novartis, Sebamed and Galderma, and is involved in the organization of atopic dermatitis education programs in Germany for the treatment of atopic dermatitis. Dr. Bangert has been a consultant or speaker for Bayer, Mylan, LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Celgene and AbbVie and principal investigator for Merck, Novartis, Sanofi, Abbvie, Elli Lilly, and Galderma. Dr. Spuls has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), received departmental independent research grants from pharmaceutical industries different since December 2019 for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital and, is Chief Investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigator of the SECURE‐AD registry. Dr. Wollenberg has been a principal investigator, advisory board member, or consultant for AbbVie, Almirall, Galderma, Hans Karrer, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme, and received speaker honoraria from Chugai, Galderma, LEO Pharma, Lilly, Loreal, MedImmune, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. Dr. Deleuran has been a principal investigator, speaker, advisory board member, or consultant for LEO Pharma, AbbVie, Almirall, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Pierre Fabre. This research was performed independently through the authors’ academic university and hospital affiliations.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85103429908&partnerID=8YFLogxK

U2 - https://doi.org/10.1111/jdv.17237

DO - https://doi.org/10.1111/jdv.17237

M3 - Comment/Letter to the editor

C2 - 33752263

SN - 0926-9959

VL - 35

SP - e362-e365

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 6

ER -

Ring J, Worm M, Wollenberg A, Thyssen JP, Jakob T, Klimek L et al. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology. 2021 Jun;35(6):e362-e365. Epub 2021. doi: https://doi.org/10.1111/jdv.17237

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

Access to Document

Other files and links

Cite this